https://doi.org/10.4081/cc.2025.15860
PO-38 | Impact of atogepant on achieving best possible quality of life among patient global impression of change responders
Cristina Tassorelli,1 Pranav Gandhi,2 Molly Duan,2 Karen Carr,2 Kandavadivu Umashankar,2 Jonathan Stokes,2 Grace Forde,3 Tanya Bilchik,4 Martina Martini*, Rashmi Halker Singh5 | 1University of Pavia, Pavia, Italy; 2AbbVie, North Chicago, IL, USA; 3North American Partners in Pain Management, North New Hyde Park, NY, USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 6 November 2025
Background: The impact of atogepant, an oral calcitonin gene-related peptide receptor antagonist used for migraine prevention, was evaluated on participants reporting best possible quality of life (QoL) based on Migraine-Specific Quality of Life Questionnaire among responders and non-responders to Patient Global Impression of Change (PGIC).
Methods: ADVANCE, ELEVATE, and PROGRESS were phase 3, multicenter, randomised, double-blind, placebo-controlled, 12-week trials that included adults with episodic migraine (EM), EM with prior inadequate responses to 2-4 oral preventive treatments, and chronic migraine (CM), respectively. This post hoc analysis evaluated the proportion of participants who achieved a score of 100 for all 3 MSQv2.1 domain scores at Week 12 based on their PGIC response (responders and non-responders). PGIC is a 7-point single question scale measuring participants impression of change in migraine symptoms since first dose of treatment. MSQv2.1 is a 3-domain questionnaire composed of 14 items designed to assess how migraine limits social and work activities, prevents social and work activities, and emotions associated with migraine. A score of 100 indicates the best possible QoL, with less disruption from migraine.
Results: In PGIC responders, a higher proportion of EM participants treated with atogepant 60mg once daily achieved MSQv2.1 scores of 100 in all 3 domains compared with placebo [ADVANCE(P≤.05); ELEVATE(P≤.001)], and numerically higher proportion in CM atogepant-treated participants [PROGRESS(P≥.05)].
Conclusion: A greater proportion of atogepant-treated EM and CM participants who are PGIC responders reported best possible QoL with lower disruption from migraine, compared with placebo.
Note: This individual (Martina Martini) has been added to this publication author by-line, with the permission of the original authors, for the express purpose of conducting the presentation at a local congress or in a local language. She did not contribute to the content of the publication.
Downloads
No refs
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.